Hologic, Inc. (NASDAQ:HOLX) Shares Sold by MQS Management LLC

MQS Management LLC lowered its holdings in Hologic, Inc. (NASDAQ:HOLX) by 41.6% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,012 shares of the medical equipment provider’s stock after selling 2,143 shares during the period. MQS Management LLC’s holdings in Hologic were worth $245,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Wolff Wiese Magana LLC bought a new position in Hologic in the third quarter worth about $25,000. Innealta Capital LLC bought a new stake in shares of Hologic during the second quarter valued at approximately $25,000. iA Global Asset Management Inc. bought a new stake in shares of Hologic during the first quarter valued at approximately $37,000. Sunbelt Securities Inc. bought a new stake in shares of Hologic during the second quarter valued at approximately $37,000. Finally, Cromwell Holdings LLC raised its holdings in shares of Hologic by 330.2% during the third quarter. Cromwell Holdings LLC now owns 542 shares of the medical equipment provider’s stock valued at $44,000 after buying an additional 416 shares during the last quarter. Institutional investors own 94.73% of the company’s stock.

Hologic Trading Up 1.4 %

Hologic stock opened at $78.60 on Friday. The company has a debt-to-equity ratio of 0.49, a quick ratio of 3.03 and a current ratio of 3.69. The firm has a market cap of $18.26 billion, a price-to-earnings ratio of 23.60, a price-to-earnings-growth ratio of 2.50 and a beta of 0.98. Hologic, Inc. has a 1 year low of $67.59 and a 1 year high of $84.67. The firm’s 50 day moving average price is $80.71 and its two-hundred day moving average price is $78.23.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.01. The firm had revenue of $987.90 million for the quarter, compared to analyst estimates of $978.25 million. Hologic had a net margin of 19.59% and a return on equity of 19.79%. The firm’s quarterly revenue was up 4.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.89 earnings per share. On average, research analysts predict that Hologic, Inc. will post 4.27 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

HOLX has been the topic of a number of recent analyst reports. Mizuho cut their price target on Hologic from $90.00 to $87.00 and set an “outperform” rating on the stock in a report on Tuesday, November 5th. Royal Bank of Canada lifted their price target on Hologic from $86.00 to $89.00 and gave the company a “sector perform” rating in a report on Tuesday, November 5th. Evercore ISI boosted their target price on Hologic from $78.00 to $82.00 and gave the stock an “in-line” rating in a report on Tuesday, October 1st. Raymond James boosted their target price on Hologic from $93.00 to $95.00 and gave the stock an “outperform” rating in a report on Tuesday, November 5th. Finally, UBS Group boosted their target price on Hologic from $84.00 to $90.00 and gave the stock a “neutral” rating in a report on Tuesday, November 5th. Four investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $89.91.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.